Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

Bristol Myers Squibb has touted its strengthened collaboration with Nvidia as aiming to build the “most powerful AI factory ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...

For emerging biotech companies, the race to IND is no longer defined by speed alone. | Lonza explains why early de-risking ...

After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum. The ...

Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for ...

Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a ...